2-氟-4-三氟甲氧基碘苯 | 1321963-74-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-氟-4-三氟甲氧基碘苯
• 英文名称: 2-fluoro-1-iodo-4-trifluoromethoxybenzene
• 英文别名: 2-fluoro-4-triflouromethoxyiodobenzene；2-Fluoro-1-iodo-4-(trifluoromethoxy)benzene
• CAS: 1321963-74-9
• 化学式: C₇H₃F₄IO
• 分子量: 305.998
• InChiKey: MAFILVJNIQSQSP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H320,H335

反应信息

• 作为反应物：
  描述：

  2-氟-4-三氟甲氧基碘苯 在 正丁基锂 、 溶剂黄146 作用下， 以 四氢呋喃 、 正己烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 25.75h， 生成 (S)-N-(2-fluoro-4-(trifluoromethoxy)benzyl)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-amine
  参考文献：
  名称：

  Structure–Activity Relationships of Antitubercular Nitroimidazoles. 3. Exploration of the Linker and Lipophilic Tail of ((S)-2-Nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-Amino PA-824).

  摘要：

  The (S)-2-nitro-6-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine named PA-824 (1) has demonstrated antitubercular activity in vitro and in animal models and is currently in clinical trials. We synthesized derivatives at three positions of the 4-(trifluoromethoxy)benzylamino tail, and these were tested for whole-cell activity against both replicating and nonreplicating Mycobacterium tuberculosis (Mtb). In addition, we determined their kinetic parameters as substrates of the deazaflavin-dependent nitroreductase (Ddn) from Mtb that reductively activates these pro-drugs. These studies yielded multiple compounds with 40 nM aerobic whole cell activity and 1.6 mu M anaerobic whole cell activity: 10-fold improvements over both characteristics from the parent molecule. Some of these compounds exhibited enhanced solubility with acceptable stability to microsomal and in vivo metabolism. Analysis of the conformational preferences of these analogues using quantum chemistry suggests a preference for a pseudoequatorial orientation of the linker and lipophilic tail.

  DOI：

  10.1021/jm1010644
• 作为产物：
  描述：

  1-溴-2-氟-4-三氟甲氧基苯 在 copper(l) iodide 、 sodium iodide 、 N,N'-二甲基乙二胺 作用下， 以 1,4-二氧六环 为溶剂， 以1.3 g的产率得到2-氟-4-三氟甲氧基碘苯
  参考文献：
  名称：

  [EN] BENZYL-, (PYRIDIN-3-YL)METHYL- OR (PYRIDIN-4-YL)METHYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS
  [FR] DÉRIVÉS D'OXADIAZOLOPYRIDINE À SUBSTITUTION BENZYLE, (PYRIDIN-3-YL)MÉTHYLE OU (PYRIDIN-4-YL)MÉTHYLE UTILISÉS EN TANT QU'INHIBITEURS DE LA GHRÉLINE O-ACYLTRANSFÉRASE (GOAT)

  摘要：

  本发明涉及一般式（I）的化合物，其中基团R1和R2的定义如权利要求1中所述，该化合物具有有价值的药理特性，特别是与胃饥饿素O-酰基转移酶（GOAT）结合并调节其活性。这些化合物适用于治疗和预防可以受到该受体影响的疾病，如代谢性疾病，特别是肥胖症。

  公开号：

  WO2019149657A1

文献信息

• ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Celgene Corporation

  公开号：US20200163948A1

  公开（公告）日：2020-05-28

  Compounds of formula I for treating, preventing or managing cancer are disclosed. Also disclosed are methods of treating, preventing or managing cancer, such as leukemia, comprising administering the compounds. In certain embodiments, the method of treatment comprise administering a compound provided herein in combination with a second agent. Pharmaceutical compositions and single unit dosage forms comprising the compounds are also disclosed.

  本文揭示了化学式I的化合物，用于治疗、预防或管理癌症。还揭示了治疗、预防或管理癌症的方法，例如治疗白血病，包括给予这些化合物。在某些实施例中，治疗方法包括与第二药物联合给药。此外，还揭示了包含这些化合物的药物组合物和单剂量形式。
• [EN] ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS ANTIPROLIFÉRATIFS ET MÉTHODES D'UTILISATION DESDITS COMPOSÉS
  申请人：CELGENE CORP

  公开号：WO2016007848A1

  公开（公告）日：2016-01-14

  Compounds of formula (I) for treating, preventing or managing cancer are disclosed. Also disclosed are methods of treating, preventing or managing cancer, such as leukemia, comprising administering the compounds. In certain embodiments, the method of treatment comprise administering a compound provided herein in combination with a second agent. Pharmaceutical compositions and single unit dosage forms comprising the compounds are also disclosed. In Formula (I) R1 is optionally substituted cycloalkyi, aryl, heteroaryl or heterocyclyl; and R2 and R3 are each halo.

  本发明揭示了化学式(I)的化合物，用于治疗、预防或管理癌症。同时，还揭示了治疗、预防或管理癌症的方法，例如白血病，包括给予该化合物。 在某些实施例中，治疗方法包括联合给予本文提供的化合物和第二药物。还揭示了包含该化合物的制药组合物和单剂量形式。 在化学式(I)中，R1是可选的取代环烷基，芳基，杂芳基或杂环烷基；R2和R3均为卤素。
• ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
  申请人：Kangpu Biopharmaceuticals, Ltd.

  公开号：EP3214081A1

  公开（公告）日：2017-09-06

  Provided are an isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof. The isoindoline derivative and the pharmaceutical composition thereof can regulate the production or activity of immunological cytokines, thus effectively treating cancer and inflammatory disease.

  本文提供了一种异吲哚啉衍生物、中间体、制备方法、药物组合物及其用途。异吲哚啉衍生物及其药物组合物可以调节免疫细胞因子的产生或活性，从而有效治疗癌症和炎症性疾病。
• Benzyl-, (pyridin-3-yl)methyl -or (pyridin-4-yl)-methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors
  申请人：Boehringer Ingelheim International GmbH

  公开号：US11254688B2

  公开（公告）日：2022-02-22

  The present invention relates to compounds of general formula (I), wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.

  本发明涉及通式(I)的化合物，其中基团 R1 和 R2 的定义如权利要求 1 所述，这些化合物具有重要的药理特性，特别是能与胃泌素 O-酰基转移酶（GOAT）结合并调节其活性。这些化合物适用于治疗和预防受该受体影响的疾病，如代谢性疾病，特别是肥胖症。
• Antiproliferative compounds and methods of use thereof
  申请人：Celgene Corporation

  公开号：US11241423B2

  公开（公告）日：2022-02-08

  Compounds of formula I for treating, preventing or managing cancer are disclosed. Also disclosed are methods of treating, preventing or managing cancer, such as leukemia, comprising administering the compounds. In certain embodiments, the method of treatment comprise administering a compound provided herein in combination with a second agent. Pharmaceutical compositions and single unit dosage forms comprising the compounds are also disclosed.

  本发明公开了用于治疗、预防或控制癌症的式 I 化合物。还公开了治疗、预防或控制癌症（如白血病）的方法，包括施用这些化合物。在某些实施方案中，治疗方法包括将本文提供的化合物与第二种制剂结合施用。还公开了包含本发明化合物的药物组合物和单一单位剂型。